REFERENCES
- Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA. 2012;308(4):387–402.
- Melial S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.
- Lucas A, Nolan D, Melial S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother. 2007;59(4):591–593.
- Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp7O-HOM variant. Proc Natl Acad Sci USA. 2004;101(12):4180–4185.
- Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacoge-nomics. 2004;5(2):203–211.
- Phillips EJ, Wong GA, Kaul R, et al. Clinical and immu-nogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979–981.
- Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen—B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7)1111–1118.
- Melial S, Phillips E, Carosi G, et al. HLA-B*5701 screen-ing for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–579.
- Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treat-ment of adult HIV infection 2008: Recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300(5):555–570.
- Chui CK, Brumme ZL, Brumme CJ, et al. A simple screen-ing approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis. 2007;44(11): 1503–1508.
- Waters LJ, Mackie NE, Pozniak A, Winston A. Polymor-phisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701. Clin Infect Dis. 2007;45(9)1243–1244.
- Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Melial S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syn-drome. Pharmacogenet Genomics. 2006;16(5):353–357.
- Airo P, Scarsi M, Malagoli A, et al. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. J Acquir Immune Defic Syndr. 2009;51(3):361–362.
- Kostenko L, Kjer-Nielsen L, Nicholson I, et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens. 2011;78(1)1 1–20.
- Arrizabalaga J, Rodríguez-Alcántara F, Castarier JL, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials. 2009;10(1):48–51.
- Rodriguez-Sáinz C, Ramos R, Valor L, et al. Prognostic value of HIV-1 DNA in peripheral blood mononuclear cells for virological outcome in asymptomatic HIV-1 chronic infection. J Clin Virol. 2010;48(3):168–172.
- Valor L, Navarro J, Carbone J, et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-spe-cific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine. 2008;26(22):2738–2745.
- Goding JW. Monoclonal Antibodies: Principles and Prac-tice. 3rd ed. San Diego: Academic Press, Harcourt Brace and Company; 1993.
- Stevens R, Coates E, Street J, Cook E, Darke C. Compre-hensive evaluation of two HLA-B17 monoclonal antibodies for flow cytometry-based HLA-B57/858 screening prior to abacavir prescription [published online ahead of print December 26,2012]. Int J lmmunogenetics.
- McMichel AJ, Parham P, Rust N, Brodsky F. A monoclo-nal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum lmmunol. 1980;1: 121–129.